INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists’ View

Diagnostics

Ivana Kholová¹  Akash Nadella²  Mohnish Nadella²  Gopi Patel²  Shivni Patel²  Zahra Maleki³ 

[1] Department of Pathology, Fimlab Laboratories, Tampere, Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland;Department of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA;Division of Cytopathology, Department of Pathology, The Johns Hopkins Hospital, The Johns Hopkins Medical Institution, Baltimore, MD 21218, USA;

关键词: cytology;    neuroendocrine tumor;    INSM-1 immunostaining;    medullary thyroid carcinoma;    pancreatic neuroendocrine tumor;    pulmonary neuroendocrine neoplasms;   

DOI  :  10.3390/diagnostics11122172

来源: DOAJ

【 摘 要 】

Background: Insulinoma-associated protein 1 (INSM1) has been considered as a novel immunostain for neuroendocrine tumors (NETs) and is hypothesized to be more reliable than first-generation NET biomarkers, such as CGA (chromogranin A), SYP (synaptophysin) and CD56 (neural cell adhesion molecule). In this review, we summarize existing literature on INSM1′s reliability as an immunostain for detection of various NETs, its results in comparison to first-generation NET biomarkers, and its expression in both non-NETs and benign tissues/cells on cytology specimens (cell blocks/smears).

【 授权许可】

Unknown